Refine by
Phase 1 Clinical Equipment Supplied In France
14 equipment items found
Manufactured by:Poietis based inPessac, FRANCE
NGB-C is a clinical-grade, GMP-compliant Bioprinter designed to meet the needs of Advanced Therapy Medicinal Products (ATMP) production and the requirements of Poietis’ ...
by:Abivax based inParis, FRANCE
ABX464 is an oral, first-in-class, small molecule that has demonstrated safety and profound anti-inflammatory activity in the completed Phase 2a and Phase 2b induction studies as well as in long-term maintenance studies in patients with moderate-to-severe ulcerative colitis (UC). In addition to the clinical observations in UC patients, Abivax generated excellent phase 2a clinical results in RA, ...
Manufactured by:Enterome based inParis, FRANCE
Sibofimloc is a first-in-class, orally administered small molecule that is specifically designed to reduce the inflammatory cascade underlying Crohn’s disease and remain gut-restricted, to minimize absorption into the bloodstream. ...
by:Abivax based inParis, FRANCE
ABX196 has been developed as a synthetic agonist of iNKT cells from a proprietary platform technology that identifies cells with immune enhancing potential in cancer ...
by:Abivax based inParis, FRANCE
ABX464 is an oral, first-in-class, small molecule that has demonstrated safety and profound anti-inflammatory activity in preclinical trials and in Phase 2a and Phase 2b induction trials to treat ulcerative colitis (UC). Patients who completed the induction studies had the option to roll over into the respective open-label extension ...
Manufactured by:GENFIT based inLoos, FRANCE
Primary Biliary Cholangitis (PBC) is a chronic disease in which bile ducts in the liver are gradually destroyed.1 The damage to bile ducts can inhibit the liver’s ability to rid the body of toxins, and can lead to cirrhosis. Targeting PPAR receptors may result in a reduction of bile acid synthesis, improved detoxification of bile in the bile duct and anti-inflammatory activity. The use of ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
a monoclonal antibody fragment and CD28 antagonist, selectively blunts CD28 co-stimulation while sparing the CTLA-4 co-inhibitory signal. The net effect of CD28 antagonism is down regulating effector T-cells while promoting T-Reg activity. The CD28/CTLA-4 pathway controls both T-cell activation and regulatory T-cell down regulation. CD28 receptor is expressed on the surface of the majority of ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
A humanized monoclonal antibody, is an antagonist of the alpha chain of the interleukine-7 receptor, CD127, present on T effector cells, thus down regulating the immune activity. Interleukin-7 (IL-7) is a cytokine that controls the proliferation, apoptosis and activation of CD4 and CD8 effector T-cells in ...
by:Treefrog Therapeutics based inPessac, FRANCE
C-Stem™ is a biomimetic cell culture technology allowing for the mass-production of stem cell- derived therapies with unprecedented cell quality, while cutting manufacturing costs by 10x. ...
by:Oncodesign based inDijon, FRANCE
Oncodesign’s Pharmimage® technology module is a pharmaco-imaging module designed to monitor the effect of treatments and to define effective translational biomarkers in precision medicine. It includes translational, optical (bioluminescence, fluorescence), functional and molecular (MRI, PET, SPECT, CT scanner, MRI/PET coupling) multi-modal imaging capabilities, adapted to small rodents ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
In recent years, immunotherapies have driven significant clinical progress and increased hopes for patients suffering from various types of cancer. The tumor microenvironment (TME), in particular the presence and immune-status of myeloid derived suppressor cells (MDSC), tumor-associated macrophages (TAM) as well as dendritic cells, has been closely linked to tumor activity and responsiveness to ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
CoVepiT, a multi-target and multi-variant vaccine candidate against COVID-19. CoVepiT is a next-generation multi-target, multi-variant vaccine against SARS-CoV-2 in clinical Phase 1. The vaccine candidate was designed using optimized epitopes selected after screening more than 67,000 global SARS-CoV-2 genomes, as well as those of previous ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
Tedopi®, OSE Immunotherapeutics’s most advanced product and therapeutic neo-epitope-based vaccine, is a proprietary combination of nine optimized neo-epitopes, selected and optimized from 5 tumoral antigens to activate specifically T cells, plus one epitope giving universal helper T cell response targeting T cell ...
Manufactured by:Ionicon Analytik Ges.m.b.H. based inInnsbruck, AUSTRIA
Inlet system optimized for real-time breath analysis with PTR-MS. Based on our patented BET sampling technique and certified for clinical ...